Ingress of Coolant Event simulation with TRACE code with accuracy evaluation and coupled DAKOTA Uncertainty Analysis

Among the Postulated Initiating Events in nuclear fusion plants, the Ingress of Coolant Event (ICE) in the Plasma Chamber is one of the main safety issues. In the present paper, the best estimate thermal-hydraulic system code TRACE, developed by USNRC, has been adopted to study the ICE, and it has been qualified based on experimental results obtained in the Integrated ICE facility at JAERI. A nodalization has been developed in the SNAP environment/architecture, using also the TRACE 3D Vessel component where multidimensional phenomena could occur. The accuracy of the code calculation has been assessed both from a qualitative and quantitative point of view. In addition, an Uncertainty Analysis (UA), with the probabilistic method to propagate the input uncertainties, has been performed to characterize the dispersion of the results. The analysis has been carried out with the DAKOTA toolkit coupled with TRACE code in the SNAP environment/architecture. Results show the adequacy of the 3D nodalization and the capability of the code to follow the transient evolution also at a very low pressure. Response correlations have been computed to characterize the correlation between the selected uncertain input parameters and the Plasma Chamber pressure

Stem cell transplantation for ischemic stroke

Background Stroke is a leading cause of morbidity and mortality worldwide, with very large healthcare and social costs, and a strong demand for alternative therapeutic approaches. Preclinical studies have shown that stem cells transplanted into the brain can lead to functional improvement. However, to date, evidence for the benefits of stem cell transplantation in people with ischemic stroke is lacking. This is the first update of the Cochrane review published in 2010. Objectives To assess the efficacy and safety of stem cell transplantation compared with control in people with ischemic stroke. Search methods We searched the Cochrane Stroke Group Trials Register (last searched August 2018), CENTRAL (last searched August 2018), MED-LINE (1966 to August 2018), Embase (1980 to August 2018), and BIOSIS (1926 to August 2018). We handsearched potentially relevant conference proceedings, screened reference lists, and searched ongoing trials and research registers (last searched August 2018). We also contacted individuals active in the field and stem cell manufacturers (last contacted August 2018). Selection criteria We included randomized controlled trials (RCTs) that recruited people with ischemic stroke, in any phase of the disease (acute, subacute or chronic), and an ischemic lesion confirmed by computerized tomography or magnetic resonance imaging scan. We included all types of stem cell transplantation, regardless of cell source (autograft, allograft, or xenograft; embryonic, fetal, or adult; from brain or other tissues), route of cell administration (systemic or local), and dosage. The primary outcome was efficacy (assessed as neurologic impairment or functional outcome) at longer term follow-up (minimum six months). Secondary outcomes included post-procedure safety outcomes (death, worsening of neurological deficit, infections, and neoplastic transformation). Data collection and analysis Two review authors independently applied the inclusion criteria, assessed trial quality and risk of bias, and extracted data. If needed, we contacted study authors for additional information. We performed random effects meta-analyses when two or more RCTs were available for any outcome. We assessed the certainty of the evidence by using the GRADE approach. Main results In this updated review, we included seven completed RCTs with 401 participants. All tested adult human non-neural stem cells; cells were transplanted during the acute, subacute, or chronic phase of ischemic stroke; administered intravenously, intra-arterially, intracerebrally, or into the lumbar subarachnoid space. Follow-up ranged from six months to seven years. Efficacy outcomes were measured with the National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), or Barthel Index (BI). Safety outcomes included case fatality, and were measured at the end of the trial. Overall, stem cell transplantation was associated with a better clinical outcome when measured with the NIHSS (mean difference [MD]-1.49, 95% confidence interval [CI]-2.65 to-0.33; five studies, 319 participants; low-certainty evidence), but not with the mRS (MD-0.42, 95% CI-0.86 to 0.02; six studies, 371 participants; very low-certainty evidence), or the BI (MD 14.09, 95% CI-1.94 to 30.13; three studies, 170 participants; very low-certainty evidence). The studies in favor of stem cell transplantation had, on average, a higher risk of bias, and a sample size of 32 or fewer participants. No significant safety concerns associated with stem cell transplantation were raised with respect to death (risk ratio [RR] 0.66, 95% CI 0.39 to 1.14; six studies, participants; low-certainty evidence). We were not able to perform the sensitivity analysis according to the quality of studies, because all of them were at high risk of bias. Authors’ conclusions Overall, in participants with ischemic stroke, stem cell transplantation was associated with a reduced neurological impairment, but not with a better functional outcome. No obvious safety concerns were raised. However, these conclusions came mostly from small RCTs with high risk of bias, and the certainty of the evidence ranged from low to very low. More well-designed trials are needed

Malignant mammary tumor in female dogs: environmental contaminants

Mammary tumors of female dogs have greatly increased in recent years, thus demanding rapid diagnosis and effective treatment in order to determine the animal survival. There is considerable scientific interest in the possible role of environmental contaminants in the etiology of mammary tumors, specifically in relation to synthetic chemical substances released into the environment to which living beings are either directly or indirectly exposed. In this study, the presence of pyrethroid insecticide was observed in adjacent adipose tissue of canine mammary tumor. High Precision Liquid Chromatography - HPLC was adapted to detect and identify environmental contaminants in adipose tissue adjacent to malignant mammary tumor in nine female dogs, without predilection for breed or age. After surgery, masses were carefully examined for malignant neoplastic lesions. Five grams of adipose tissue adjacent to the tumor were collected to detect of environmental contaminants. The identified pyrethroids were allethrin, cyhalothrin, cypermethrin, deltamethrin and tetramethrin, with a contamination level of 33.3%. Histopathology demonstrated six female dogs (66.7%) as having complex carcinoma and three (33.3%) with simple carcinoma. From these tumors, seven (77.8%) presented aggressiveness degree III and two (22.2%) degree I. Five tumors were positive for estrogen receptors in immunohistochemical analysis. The contamination level was observed in more aggressive tumors. This was the first report in which the level of environmental contaminants could be detected in adipose tissue of female dogs with malignant mammary tumor, by HPLC. Results suggest the possible involvement of pyrethroid in the canine mammary tumor carcinogenesis. Hence, the dog may be used as a sentinel animal for human breast cancer, since human beings share the same environment and basically have the same eating habits

Avvio e gestione di attività estrattive: un approccio in "Prevention Through Design"

Una efficace analisi e gestione dei rischi presso le unità estrattive, su cui fondare l’attività in coerenza con le norme vigenti in materia di sicurezza del lavoro, implica un approccio pro-attivo, tenuto conto dei diversi fattori coinvolti. In tale contesto un approccio pro-attivo richiede una approfondita analisi di rischio, fondata sulla valutazione delle possibili opzioni progettuali e la conoscenza del sito e del programma di coltivazione; nel presente lavoro viene esposta una metodologia basata su un sistema di registrazione dei dati tecnici supportata da un apposito software interattivo, in grado di aiutare la valutazione degli aspetti generali e specifici della sicurezza di comparto e di singole unità estrattive. Il lavoro è stato svolto dal Dipartimento di Ingegneria del Territorio, dell’Ambiente e delle Geotecnologie del Politecnico di Torino (già Autore di Linee Guida in materia di sicurezza per il comparto estrattivo) con il supporto dell’Ufficio Tutela Ambientale della Provincia di Torino

Dense dark-bright soliton arrays in a two-component Bose-Einstein condensate

We present a combined experimental and theoretical study of regular dark-bright soliton arrays in a two-component atomic Bose-Einstein condensate. We demonstrate a microwave pulse-based winding technique which allows for a tunable number of solitary waves en route to observing their dynamics, quantified through Fourier analysis of the density. We characterize different winding density regimes by the observed dynamics including the decay and revival of the Fourier peaks, the emergence of dark-antidark solitons, and disordering of the soliton array. The experimental results are in good agreement with three-dimensional numerical computations of the underlying mean-field theory. These observations open a window into the study of soliton crystals and the dynamics, excitations, and lifetimes of such patterns

Identificação de parvovírus suíno em javalis a partir do sequenciamento parcial do gene VP-2

Este estudo descreve a detecção e a identificação de DNA de parvovírus suíno (PVS) em amostras de órgãos de dois javalis, por PCR e sequenciamento direcionado ao gene VP-2. Pools de órgãos (baço, rins, fígado, linfonodos e tonsila) de três javalis adultos e assintomáticos de Paraguaçu Paulista, SP, criados com propósitos comerciais, foram submetidos à detecção de PVS, resultando em duas amostras positivas após reações de nested-PCR direcionadas aos genes NS-1 e VP-2. Os fragmentos parciais de VP-2 foram sequenciados e comparados a sequências homólogas de cepas NADL-2 e Kresse, demonstrando identidade nucleotídica de 100%. Com relação a 29 cepas de PVS previamente isoladas no Brasil, o grau de identidade nucleotídica variou de 99 a 100% (uma a três substituições de nucleotídeos). Estes resultados demonstram, pela primeira vez, a detecção direta por PCR de parvovírus suíno em javalis, confirmada por análise de sequenciamento genétic

Accesibilidad y adherencia a drogas biológicas en un servicio público de reumatología de la ciudad de Rosario, Santa Fe, Argentina

Objetivo: Describir la situación de accesibilidad y adherencia a tratamientos con drogas biológicas en pacientes de un servicio público de reumatología. Métodos: Estudio de corte transversal, observacional y retrospectivo que incluyó pacientes con gestión de DB. Variables: sociodemográficas, clínicas, tratamientos, tiempo desde el diagnóstico al acceso, adherencia (porcentaje de toma mensual y adecuada de la droga ≥75%); tiempo desde prescripción a administración; trámite administrativo realizado por entidad pública u obra social; certificado único de discapacidad (CUD)

The GALA project. practical recommendations for the use of migalastat in clinical practice on the basis of a structured survey among Italian experts

Background: Oral migalastat has recently been approved for the treatment of Anderson-Fabry disease (FD) in patients aged ≥16 years with amenable mutations on the basis of two phase III trials, FACETS and ATTRACT. However, with the introduction of migalastat into clinical practice, it is important to correctly identify the patients who may gain the most benefits from this therapy. Due to the relatively recent availability of migalastat, its role in clinical practice still has to be included in guidelines or recommendations. On these bases, a multidisciplinary group of Italian Experts in the treatment of FD has run the GALA project, with the aim to collect the opinions of expert physicians and to propose some starting points for an experience-based use of migalastat. Results: Overall, although studies and data from longer-term follow-up with migalastat are still emerging, available evidence is consistent in showing that this molecule does represent a suitable therapy for the treatment of FD, in patients aged ≥16 years and with amenable mutations. The use of migalastat as an oral option appears to be overall safe, and experience thus far indicates potential for improving quality of life, controlling GI symptoms, stabilizing renal function and reducing cardiac hypertrophy. Conclusion: Migalastat can be considered either as a first-line therapy - given its efficacy, extensive tissue penetration, convenient oral regimen, and the current limited therapeutic options available - or in patients on enzyme-replacement therapy (ERT) who experience side effects, with poor compliance to chronic i.v. therapy, or with clinical evidence of progression of the disease